KR101828290B1 - 자궁내막암 마커 - Google Patents

자궁내막암 마커 Download PDF

Info

Publication number
KR101828290B1
KR101828290B1 KR1020127004840A KR20127004840A KR101828290B1 KR 101828290 B1 KR101828290 B1 KR 101828290B1 KR 1020127004840 A KR1020127004840 A KR 1020127004840A KR 20127004840 A KR20127004840 A KR 20127004840A KR 101828290 B1 KR101828290 B1 KR 101828290B1
Authority
KR
South Korea
Prior art keywords
endometrial cancer
p4hb
gmip
ikbke
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127004840A
Other languages
English (en)
Korean (ko)
Other versions
KR20120047334A (ko
Inventor
미구엘 아발 포사다
안드레아스 돌
안토니오 길 모레노
타라 매스
크리스티나 페레즈
하우메 레벤토스 푸이그자넬
엘리자베스 로셀
Original Assignee
지드익 바이오텍 에이아이이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지드익 바이오텍 에이아이이. filed Critical 지드익 바이오텍 에이아이이.
Publication of KR20120047334A publication Critical patent/KR20120047334A/ko
Application granted granted Critical
Publication of KR101828290B1 publication Critical patent/KR101828290B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
KR1020127004840A 2009-07-24 2010-07-23 자궁내막암 마커 Expired - Fee Related KR101828290B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166398 2009-07-24
EP09166398.9 2009-07-24
PCT/EP2010/004550 WO2011009637A2 (en) 2009-07-24 2010-07-23 Markers for endometrial cancer

Publications (2)

Publication Number Publication Date
KR20120047334A KR20120047334A (ko) 2012-05-11
KR101828290B1 true KR101828290B1 (ko) 2018-02-12

Family

ID=42751506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004840A Expired - Fee Related KR101828290B1 (ko) 2009-07-24 2010-07-23 자궁내막암 마커

Country Status (17)

Country Link
US (2) US9046522B2 (enExample)
EP (2) EP2848700B1 (enExample)
JP (1) JP5934093B2 (enExample)
KR (1) KR101828290B1 (enExample)
CN (2) CN105132529A (enExample)
AU (1) AU2010275699B2 (enExample)
BR (1) BR112012001469B1 (enExample)
CA (1) CA2767914C (enExample)
DK (1) DK2456889T3 (enExample)
ES (2) ES2654340T3 (enExample)
HR (1) HRP20141062T1 (enExample)
IN (1) IN2012DN00707A (enExample)
MX (1) MX2012000921A (enExample)
PL (1) PL2456889T3 (enExample)
PT (1) PT2456889E (enExample)
RU (1) RU2596394C2 (enExample)
WO (1) WO2011009637A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN00707A (enExample) * 2009-07-24 2015-06-19 Geadic Biotec Aie
WO2013044187A2 (en) * 2011-09-22 2013-03-28 Memorial Sloan-Kettering Cancer Center Detecting ovarian cancer
EP2787350A1 (en) * 2013-04-05 2014-10-08 Atlas Antibodies AB ASRGL1 in endometrial cancer
KR102113310B1 (ko) * 2013-09-03 2020-05-20 아주대학교 산학협력단 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법
CA2956723C (en) 2014-08-12 2023-04-11 Nextgen Jane, Inc. System and method for monitoring health based on collected bodily fluid
ES2897782T3 (es) * 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
CN107102141A (zh) * 2016-02-23 2017-08-29 中国科学院生物物理研究所 分子标记物cd71及在子宫内膜癌诊断、分期及预后中的应用
EP3442706B1 (en) 2016-04-13 2025-07-23 NextGen Jane, Inc. Sample collection and preservation methods
JP7240712B2 (ja) * 2016-05-04 2023-03-16 フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ 子宮内膜がんのマーカーとしてのｐｅｒｍ
GB201702392D0 (en) * 2017-02-14 2017-03-29 Univ Edinburgh Methods for cancer diagnosis using a gene expression signature
CN108732351A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物
CN108732349A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Lta4h作为指示肝内结节及早期预警肝癌的生物标志物
CN108732350A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物
CN109085359A (zh) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 血清蛋白标志物组合在结直肠癌筛查和诊治中的应用
PT3655778T (pt) * 2017-07-21 2023-08-18 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Agrin como marcador de cancro do endométrio
JP2021526812A (ja) * 2018-06-13 2021-10-11 ２３イキガイ ピーティーイー リミテッド 多能性幹細胞バイオマーカーを分析するための方法およびその実施
CN109097462B (zh) * 2018-09-10 2022-01-11 青岛市海慈医疗集团 Ap1m2基因作为诊断青光眼的分子标志物的应用
WO2020130190A1 (ko) * 2018-12-20 2020-06-25 경상대학교병원 신장암의 발병 위험성 예측 또는 진단을 위한 정보제공방법
EP3914163A4 (en) * 2019-01-23 2022-04-13 Gina-Life Diagnostics Ltd. CANCER DIAGNOSTIC AND MONITORING APPARATUS, SYSTEMS AND METHODS
CN109797217A (zh) * 2019-03-27 2019-05-24 河北医科大学第二医院 帕金森生物标志物及其在制备检测产品中的应用
CN109811058B (zh) * 2019-03-31 2021-11-12 青岛泱深生物医药有限公司 与宫颈疾病发生发展相关的生物标志物及其应用
US20240218454A1 (en) * 2021-04-22 2024-07-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Diagnostic to support clinical trial matching and exploratory biomarker analyses in cancer patients
CN114317750B (zh) * 2021-12-29 2024-05-14 上海市第十人民医院 一种卵巢癌生物标志物及其在制备用于卵巢癌腹水转移疾病的药物或试剂盒中的应用
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
WO2024192014A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Endometrial cancer detection proteins and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006162446A (ja) 2004-12-07 2006-06-22 Kansai Tlo Kk 甲状腺乳頭癌を診断するための新規のマーカー
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
JP2009034071A (ja) 2007-08-03 2009-02-19 Ehime Univ 頭頸部癌の腫瘍マーカー

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
US7014996B1 (en) * 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US6884578B2 (en) 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
RU2232397C2 (ru) * 2002-04-03 2004-07-10 НИИ онкологии им. проф. Н.Н. Петрова Способ ранней диагностики патологических состояний эндометрия
US20040063120A1 (en) * 2002-07-10 2004-04-01 The Regents Of The University Of Michigan Expression profile of lung cancer
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
WO2005034978A2 (en) 2003-10-02 2005-04-21 Xantos Biomedicine Ag MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP2266561A3 (en) * 2005-09-07 2011-05-18 Merck Serono S.A. IKK Inhibitors for the Treatment of Endometriosis
CN101384903A (zh) * 2006-02-09 2009-03-11 南佛罗里达大学 利用bcl-2水平的增高检测癌肿
US20070287158A1 (en) * 2006-06-09 2007-12-13 George Gorodeski Cell collection and disease screening
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2008137591A2 (en) 2007-05-02 2008-11-13 Biocept, Inc. Non-invasive detection of endometrial cancer
US20110136123A1 (en) * 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
US8053198B2 (en) * 2007-09-14 2011-11-08 Meso Scale Technologies, Llc Diagnostic methods
US20110028344A1 (en) 2008-04-11 2011-02-03 Expression Pathology, Inc. Biomarkers for endometrial disease
IN2012DN00707A (enExample) * 2009-07-24 2015-06-19 Geadic Biotec Aie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006162446A (ja) 2004-12-07 2006-06-22 Kansai Tlo Kk 甲状腺乳頭癌を診断するための新規のマーカー
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
JP2009034071A (ja) 2007-08-03 2009-02-19 Ehime Univ 頭頸部癌の腫瘍マーカー

Also Published As

Publication number Publication date
ES2654340T3 (es) 2018-02-13
RU2012106432A (ru) 2013-08-27
CN102549169A (zh) 2012-07-04
RU2596394C2 (ru) 2016-09-10
US20120122726A1 (en) 2012-05-17
EP2456889B1 (en) 2014-09-03
EP2456889A2 (en) 2012-05-30
BR112012001469A2 (pt) 2020-08-11
US9046522B2 (en) 2015-06-02
HRP20141062T1 (hr) 2015-01-02
US20150337392A1 (en) 2015-11-26
CN105132529A (zh) 2015-12-09
EP2848700A1 (en) 2015-03-18
CN102549169B (zh) 2016-02-24
AU2010275699A1 (en) 2012-02-02
MX2012000921A (es) 2012-06-12
AU2010275699B2 (en) 2016-06-16
CA2767914C (en) 2020-02-25
JP5934093B2 (ja) 2016-06-15
WO2011009637A3 (en) 2011-04-14
EP2848700B1 (en) 2017-10-04
IN2012DN00707A (enExample) 2015-06-19
JP2013500001A (ja) 2013-01-07
ES2523683T3 (es) 2014-11-28
CA2767914A1 (en) 2011-01-27
BR112012001469B1 (pt) 2021-08-10
KR20120047334A (ko) 2012-05-11
PL2456889T3 (pl) 2015-02-27
PT2456889E (pt) 2014-11-21
WO2011009637A2 (en) 2011-01-27
DK2456889T3 (en) 2014-12-01

Similar Documents

Publication Publication Date Title
KR101828290B1 (ko) 자궁내막암 마커
AU2012340393B2 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
KR101446626B1 (ko) 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
US20020076735A1 (en) Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
US20140357518A1 (en) Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer
AU2014373927B2 (en) Prostate cancer gene profiles and methods of using the same
WO2013052108A2 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2015013233A2 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
JPWO2002083899A1 (ja) 癌関連遺伝子
US7883896B2 (en) Marker molecules associated with lung tumors
KR101683961B1 (ko) 방광암 재발 진단 마커
KR101093508B1 (ko) 대장암 진단용 조성물 및 그 용도
CN101684499A (zh) 诊断和治疗与人转酮酶样-1基因过表达有关的增殖异常的组合物和方法
KR102015527B1 (ko) 데스모글레인 3의 유전적 변이 및 이의 용도
KR20220062881A (ko) 팔보시클립, 풀베스트란트 또는 이의 조합에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
KR20110036558A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036556A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036557A (ko) 대장암 진단용 조성물 및 그 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240207